Back

Tunable Bias Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Modifications and Allosteric Site Targeting

Hadjadj, M.; Martel, J.; Roy, M.-F.; Hassanzadeh, M.; Giguere, H.; Murza, A.; Holleran, B. J.; Namkung, Y.; Froehlich, U.; Leduc, R.; Auger-Messier, M.; Laporte, S. A.; Boudreault, P.-L.

2025-08-16 molecular biology
10.1101/2025.08.13.670122 bioRxiv
Show abstract

The angiotensin II (AngII) type 1 receptor (AT1R) is a key prototypical G protein-coupled receptor in cardiovascular regulation. Biased agonists that activate G protein or {beta}-arrestin pathways provide promising therapeutic potential, but the molecular determinants for this signaling bias and its physiological implications remain poorly understood. This study profiles AngII analogs with modifications at the C-terminal Phe8, revealing that analogs 11, 12, and 29a exhibit varying degrees of Gq engagement while maintaining potent {beta}-arrestin recruitment. Notably, 12 enhances left ventricular ejection fraction with minimal pressor responses in normotensive rats, while other analogs with variable Gq activity do not promote inotropy. Molecular modeling indicates that the unique profile of 12 results from its flexible long side chain engaging a deep allosteric pocket within AT1R. This study demonstrates that engineering AngIIs C-terminus enables selective tuning of AT1R signaling to control arterial versus cardiac responses, providing strategies for developing improved cardiovascular therapeutics. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=182 SRC="FIGDIR/small/670122v1_ufig1.gif" ALT="Figure 1"> View larger version (52K): org.highwire.dtl.DTLVardef@52b49corg.highwire.dtl.DTLVardef@1cf92dcorg.highwire.dtl.DTLVardef@b2c103org.highwire.dtl.DTLVardef@19db799_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 14 journals account for 50% of the predicted probability mass.

1
Journal of Medicinal Chemistry
77 papers in training set
Top 0.2%
7.9%
2
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.1%
6.7%
3
Scientific Reports
3612 papers in training set
Top 16%
5.5%
4
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 12%
4.4%
5
Nature Communications
5641 papers in training set
Top 31%
4.3%
6
Circulation
74 papers in training set
Top 0.8%
4.0%
7
International Journal of Molecular Sciences
494 papers in training set
Top 3%
4.0%
8
Journal of Biological Chemistry
690 papers in training set
Top 3%
3.2%
9
Circulation Research
47 papers in training set
Top 0.6%
2.4%
10
eLife
5828 papers in training set
Top 44%
2.1%
11
Journal of the American Chemical Society
217 papers in training set
Top 2%
1.9%
12
Communications Biology
993 papers in training set
Top 14%
1.7%
13
ACS Omega
105 papers in training set
Top 2%
1.7%
14
iScience
1154 papers in training set
Top 20%
1.5%
50% of probability mass above
15
ChemMedChem
16 papers in training set
Top 0.2%
1.5%
16
Hypertension
36 papers in training set
Top 0.4%
1.5%
17
Pharmacological Research
18 papers in training set
Top 0.2%
1.5%
18
Cell Reports
1498 papers in training set
Top 21%
1.5%
19
Science Advances
1243 papers in training set
Top 22%
1.4%
20
Advanced Science
286 papers in training set
Top 6%
1.4%
21
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.4%
1.4%
22
The Journal of Pharmacology and Experimental Therapeutics
18 papers in training set
Top 0.3%
1.3%
23
Biochemical Pharmacology
20 papers in training set
Top 0.2%
1.3%
24
PLOS ONE
5266 papers in training set
Top 55%
1.1%
25
Journal of Chemical Information and Modeling
238 papers in training set
Top 2%
1.1%
26
Biomolecules
100 papers in training set
Top 2%
1.1%
27
ACS Chemical Biology
167 papers in training set
Top 2%
1.1%
28
Journal of Thrombosis and Haemostasis
32 papers in training set
Top 0.4%
1.0%
29
Pharmaceuticals
34 papers in training set
Top 1.0%
1.0%
30
ACS Chemical Neuroscience
67 papers in training set
Top 1%
0.9%